Clinical Trials
32 trialsVICTORIA
Centre Leon Berard
NEMO
Blokhin's Russian Cancer Research Center
STARS
Trans Tasman Radiation Oncology Group
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
First Hospital of China Medical University
NUTRIBREAST
Instituto Jalisciense de Cancerologia
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Gruppo Italiano Mammella (GIM)
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Ruijin Hospital
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Fuzhou General Hospital
MEGA
Instituto Nacional de Cancer, Brazil
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
ChineseAMS
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Pyrotinib
Peking Union Medical College Hospital
NEOADAPT
Midwestern Regional Medical Center
BETTER
Sun Yat-sen University
OTT 17-01
Ottawa Hospital Research Institute
FLAG
Samsung Medical Center
AETNBC
Peking Union Medical College Hospital
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Peking Union Medical College Hospital
Study of Arimidex and Radiotherapy Sequencing
Fudan University
PROOF
Hospital Affiliated to Military Medical Science, Beijing
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer
Fudan University
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
AI-CYP19
Korea University Anam Hospital
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
LEANEX
Fudan University
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
National Cancer Institute (NCI)